Protein Phosphorylation Patterns in Serum from Schizophrenia Patients and Healthy Controls
Overview
Authors
Affiliations
Most proteomic studies to date have attempted to identify changes in protein levels without considering the effects of post-translational modifications (PTM). However, characteristic changes of PTM such as phosphorylation could be biologically informative, as these can give insights into disease and drug mechanisms of action at the functional level. With this in mind, we have conducted a comparative proteomic and phosphoproteomic analysis of blood sera from 20 antipsychotic-naïve schizophrenia patients and 20 matched healthy controls. We used immobilised metal ion affinity chromatography (IMAC) for enrichment of phosphoproteins combined with label-free liquid chromatography-mass spectrometry (LC-MS(E)) for identification and measurement of protein and phosphoprotein levels. The LC-MS(E) analysis of both IMAC-fractions resulted in identification of 35 proteins with altered levels in schizophrenia. Analysis of the enriched fraction resulted in identification of 72 phosphoproteins with altered phosphorylation patterns. Of these, 59 showed changes in phosphorylation only, with no overall change in protein levels. This study provided evidence that schizophrenia patients feature serum abnormalities in phosphorylation of proteins involved in acute phase response and coagulation pathways. Further studies of such phosphorylation-specific changes could lead to a better understanding of the molecular aetiology of schizophrenia, and provide a means of biomarker identification for clinical studies. This article is part of a Special Issue entitled: Integrated omics.
Soluble terminal complement complex blood levels are elevated in schizophrenia.
Savukoski S, Mannes M, Wohlgemuth L, Schultze A, Guest P, Meyer-Lotz G Eur Arch Psychiatry Clin Neurosci. 2024; 274(5):1215-1222.
PMID: 38243017 PMC: 11226555. DOI: 10.1007/s00406-023-01738-z.
Sun J, Li Q, Ding Y, Wei D, Hadisurya M, Luo Z Angew Chem Int Ed Engl. 2023; 62(29):e202305668.
PMID: 37216424 PMC: 11019431. DOI: 10.1002/anie.202305668.
PTMs: A Missing Piece for Schizophrenia Studies.
Brandao-Teles C, Smith B, Carregari V Adv Exp Med Biol. 2022; 1382:119-127.
PMID: 36029408 DOI: 10.1007/978-3-031-05460-0_9.
Proteomics and Schizophrenia: The Evolution of a Great Partnership.
Smith B, Carregari V, Martins-de-Souza D Adv Exp Med Biol. 2022; 1400:129-138.
PMID: 35930231 DOI: 10.1007/978-3-030-97182-3_10.
Known and Unexplored Post-Translational Modification Pathways in Schizophrenia.
Smith B, Carregari V Adv Exp Med Biol. 2022; 1400:75-87.
PMID: 35930227 DOI: 10.1007/978-3-030-97182-3_6.